SuperX

About:

SuperX is a virtual biopharmaceutical company developing products to deliver anticoagulation without bleeding

Top Investors: Medicxi, Johnson & Johnson Robotics and Digital Solutions

Description:

The SuperX team is engaged in the discovery of antibodies against an undisclosed target in the blood coagulation cascade. SuperX hopes to reach the clinic in 2019.A preclinical stage biopharmaceutical company, based at Babraham Research Campus, developing novel anticoagulant drugs

Total Funding Amount:

$11M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2016-01-01

Founders:

Trevor Baglin

Number of Employees:

11-50

Last Funding Date:

2017-02-09

IPO Status:

Private

Industries: